LFCR — LIFECORE BIOMEDICAL INC. (Healthcare >> Drug Manufacturers - Specialty & Generic)
LFCR FAQ
What is LFCR's ROE?
LIFECORE BIOMEDICAL INC. reports a Return on Equity (ROE) of -196.78%.
What is LFCR's dividend yield?
LIFECORE BIOMEDICAL INC. offers a dividend yield of 0.00%.
What is LFCR's Deepscope Quality Score?
Deepscope rates LFCR's overall financial quality at 23 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy LFCR?
Deepscope's AI Timing Score for LFCR is 64 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does LFCR belong to?
LIFECORE BIOMEDICAL INC. is classified under the Healthcare >> Drug Manufacturers - Specialty & Generic sector on the NASDAQ exchange.
|
USD 5.63
Price
-0.16
(-2.76%)
Day Change
|
|
|---|
LFCR, the overall quality is not good ( Quality = 23) and the timing to buy is ...(Sign In to See)...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROE is relatively low.
ROA is relatively low.
Historical ROE is relatively low
Negative growth of ROE in the last year.
ROE is decreasing significantly
Acceleration of ROA growth rate is below our criteria.
Growth of ROA was below our criteria in the last year.
Net profit margin is relatively low.
Acceleration of net profit margin growth rate is below our criteria
Historical net profit margin is relatively low.
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Lorem ipsum dolor sit amet
In details, quality factors are not good , financial health is not good , and ability to make profit is not quite good , ...
| Quality Factors |
|
42% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 93 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 5.63 |
| PBV / Sector |
10.24 / 2.76
|
| Earning Per Share | -1.08 |
| PE / Sector |
N/A / 23.64
|
| PEG or PE/Growth / Sector |
N/A / 0.13
|
| Average 1M Daily Value |
1.02 M
GREAT
|
| Average 1W Daily Value |
1.40 M
GREAT
|
| Timing Factors |
|
71% |
| Financial Health |
|
37% |
| Ability to Make Profit |
|
52% |
| Return to Investors |
|
4% |
| Registration Details |
| Analyze Date | 2026-06-06 09:08:41 |
| Symbol | LFCR |
| Name | LIFECORE BIOMEDICAL INC. |
| Sector | Healthcare >> Drug Manufacturers - Specialty & Generic |
| Market | NASDAQ |
| Listed Shares | 37.51 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 212.68 / 9,835.56 |
| News, Concensus, ... |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 3515 Lyman Boulevard, Chaska, MN, United States, 55318
Phone: 952 368 4300
Website: https://www.lifecore.com
Employees: 382
Sector: Healthcare >> Drug Manufacturers - Specialty & Generic
Description: Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization that serves customers in the United States, Belgium, the Netherlands, and internationally. It provides services in the development, manufacture, aseptic fill, and finish of formulations and highly viscous sterile injectable pharmaceutical drug or medical device products in syringes, vials, and cartridges in various modalities. The company also manufactures and sells pharmaceutical-grade hyaluronic acid in bulk form, as well as for use in formulated and filled syringes and vials for injectable products used in treating various medical conditions and procedures, including ophthalmic and orthopedic applications. In addition, it offers product development services, including analytical method development and validation, formulation development, sterile filtration, process scale-up, pilot studies, stability studies, process validation, and materials production for clinical studies. The company was formerly known as Landec Corporation and changed its name to Lifecore Biomedical, Inc. in November 2022. Lifecore Biomedical, Inc. was founded in 1965 and is headquartered in Chaska, Minnesota.
ME vs SECTOR Healthcare >> Drug Manufacturers - Specialty & Generic
Click a bubble to view stock details · Bubble size represents market capitalization share
Google